BE555319A - - Google Patents

Info

Publication number
BE555319A
BE555319A BE555319DA BE555319A BE 555319 A BE555319 A BE 555319A BE 555319D A BE555319D A BE 555319DA BE 555319 A BE555319 A BE 555319A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of BE555319A publication Critical patent/BE555319A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BE555319D 1956-03-21 BE555319A (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US572788A US2868691A (en) 1956-03-21 1956-03-21 Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine

Publications (1)

Publication Number Publication Date
BE555319A true BE555319A (sv) 1900-01-01

Family

ID=24289356

Family Applications (1)

Application Number Title Priority Date Filing Date
BE555319D BE555319A (sv) 1956-03-21

Country Status (3)

Country Link
US (1) US2868691A (sv)
BE (1) BE555319A (sv)
GB (1) GB830426A (sv)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3051621A (en) * 1959-10-22 1962-08-28 Grove Lab Inc Gel composition, pressurized container with same, and method of preparation
US3050443A (en) * 1960-02-16 1962-08-21 James F Schuyler Headache remedy containing ammonia
US3039928A (en) * 1960-03-17 1962-06-19 Abbott Lab Stable aqueous isoproteronol compositions
NL262354A (sv) * 1960-03-17
US3088874A (en) * 1960-05-23 1963-05-07 Union Carbide Corp Powder aerosol
US3282781A (en) * 1960-11-25 1966-11-01 Merck & Co Inc Inhalant compositions
BE632504A (sv) * 1962-05-24
US3169095A (en) * 1962-10-30 1965-02-09 Rexall Drug Chemical Self-propelling powder-dispensing compositions
NL302251A (sv) * 1963-01-28 1965-10-11
US3710782A (en) * 1969-10-01 1973-01-16 Hauser Res And Eng Co Method of treating human skin with a composition for electromedical applications
FI770215A (sv) * 1976-01-30 1977-07-31 Fisons Ltd
AU522792B2 (en) * 1977-07-19 1982-06-24 Fisons Plc Pressure pack formulation
US4352789A (en) * 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
US4655231A (en) * 1984-01-09 1987-04-07 Advanced Tobacco Products, Inc. Snuff and preparation thereof
US4576949A (en) * 1984-05-07 1986-03-18 The Upjohn Company Use of 5,6,7,8-tetrahydroquinolines and 5,6-dihydropyrindines as leukotriene and lipoxygenase inhibitors and the novel 3-substituted compounds therein
EP0213108A3 (de) * 1985-06-26 1987-07-15 Kurt Dr. Burghart Pharmazeutische Zubereitung mit einem Antihypotonikum als wirksames Mittel
JPH0645538B2 (ja) * 1987-09-30 1994-06-15 日本化薬株式会社 ニトログリセリンスプレー剤
FR2625677A1 (fr) * 1988-01-07 1989-07-13 Cosnier Alain Composition medicamenteuse destinee a etre administree sous forme d'aerosol
EP0338670B1 (en) * 1988-03-22 1994-05-11 FISONS plc Pharmaceutical Compositions
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4003270A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5175152A (en) * 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5919435A (en) 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
US5785952A (en) * 1990-11-09 1998-07-28 Glaxo Group Limited Aerosol medicament formulation having a surface coating of surfactant
EP0656205B1 (en) 1991-06-10 2001-08-08 Schering Corporation Non-chloroflurocarbon aerosol formulations
US5234933A (en) * 1991-10-31 1993-08-10 Board Of Governors Of Wayne State University And Vanderbilt University Cyclic hydroxamic acids
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
ES2079210T3 (es) * 1991-12-12 1996-01-01 Glaxo Group Ltd Formulacion farmaceutica de aerosol.
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
CA2125666C (en) * 1991-12-12 2002-07-16 Rachel Ann Akehurst Medicaments
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
AU675633B2 (en) * 1991-12-18 1997-02-13 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
RO117414B1 (ro) * 1992-12-09 2002-03-29 Jager Paul D Waterbury Compozitie farmaceutica de aerosol in solutie
DE69408373T2 (de) * 1993-06-01 1998-07-16 Ono Pharmaceutical Co Pentansäurederivate
EP0640609A1 (en) * 1993-08-24 1995-03-01 Ono Pharmaceutical Co., Ltd. Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
CA2137106C (en) * 1993-12-03 2000-02-08 Hisao Nakai Amidinophenol derivatives
DE69424181T2 (de) * 1993-12-20 2000-10-19 Minnesota Mining And Mfg. Co., Saint Paul Flunisolide aerosolformulierungen
DK0703216T3 (da) 1994-09-20 1999-10-18 Ono Pharmaceutical Co Amidinophenolderivater som proteaseinhibitorer
US5679287A (en) * 1995-04-28 1997-10-21 Great Lakes Chemical Corporation Uses of heptafluoropropane
US5840213A (en) * 1995-04-28 1998-11-24 Great Lakes Chemical Corporation Uses of heptafluoropropane
KR980009238A (ko) 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
DK0757984T3 (da) * 1995-08-08 2003-03-03 Ono Pharmaceutical Co Hydroxamsyrederivater, der kan anvendes til inhibering af gelatinase
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5861268A (en) * 1996-05-23 1999-01-19 Biomide Investment Limited Partnership Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
WO1998034595A1 (de) 1997-02-05 1998-08-13 Jago Research Ag Medizinische aerosolformulierungen
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US7153866B1 (en) * 1997-05-27 2006-12-26 The United States Of America As Represented By The Department Of Health And Human Services Use of tempol for the treatment of Li-Fraumeni syndrome and ataxia telangiectasia
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
JPH11187882A (ja) 1997-12-26 1999-07-13 Ono Pharmaceut Co Ltd 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｃＤＮＡ、そのｃＤＮＡからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのペプチドまたは抗体を含有する薬学的組成物
EP1100465B1 (de) 1998-07-24 2004-11-24 Jago Research Ag Medizinische aerosolformulierungen
CN1150890C (zh) 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
DK1417975T3 (da) 2001-07-23 2011-04-18 Ono Pharmaceutical Co Middel til behandling af sygdomme, med tab af knoglemasse som følge, med EP4-agonist som aktivt indholdsstof
CA2476406A1 (en) 2002-02-19 2003-08-28 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
ES2589077T3 (es) * 2002-06-25 2016-11-10 Acrux Dds Pty Ltd Control de la tasa de administración transdérmica usando composiciones farmacéuticas amorfas
JPWO2004002531A1 (ja) 2002-06-26 2005-10-27 小野薬品工業株式会社 血管の収縮または拡張による疾患治療剤
EP2206517B1 (en) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
TW200408393A (en) 2002-10-03 2004-06-01 Ono Pharmaceutical Co Antagonist of lysophosphatidine acid receptor
JP4497320B2 (ja) 2002-10-10 2010-07-07 小野薬品工業株式会社 内因性修復因子産生促進剤
AU2003272962A1 (en) * 2002-10-10 2004-05-04 Shuh Narumiya Remedies for allergic diseases
JP4532409B2 (ja) 2003-01-23 2010-08-25 小野薬品工業株式会社 ヒトｐｄ−１に対し特異性を有する物質
EP1604981A4 (en) 2003-03-14 2008-12-24 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE SUBSTANCE
JP4710606B2 (ja) 2003-04-18 2011-06-29 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
EP1624866A2 (en) * 2003-05-16 2006-02-15 Arriva Pharmaceuticals, Inc. Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors
WO2006031210A1 (en) * 2003-05-29 2006-03-23 Board Of Regents, The University Of Texas Systems Jabi as a prognostic marker and a therapeutic target for human cancer
US20070270489A1 (en) 2003-07-25 2007-11-22 Ono Pharmaceutical Co., Ltd. Remedy for Cartilage-Related Diseases
KR20110140139A (ko) 2003-08-29 2011-12-30 오노 야꾸힝 고교 가부시키가이샤 Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도
EP2481732A1 (en) 2003-09-01 2012-08-01 Ono Pharmaceutical Co., Ltd. Condensed ring compound and use thereof
CA2538237A1 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
US20050136009A1 (en) * 2003-10-20 2005-06-23 Schering Corporation Pharmaceutical compositions
US7511159B2 (en) 2003-12-25 2009-03-31 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
WO2006004646A1 (en) * 2004-06-28 2006-01-12 Nektar Therapeutics Aerosol formulation comprising nicotine salt
WO2006043615A1 (ja) 2004-10-21 2006-04-27 Ono Pharmaceutical Co., Ltd. 免疫抑制受容体の用途
MX2007005845A (es) * 2004-11-24 2007-07-04 Alcon Inc Metodo para entregar rocio nasal.
JP2008528694A (ja) 2005-02-02 2008-07-31 ミトス・ファーマシューティカルズ・インコーポレーテッド 糖尿病の治療または予防において使用するためのニトロキシド類
US8524734B2 (en) * 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
EP1901749B1 (en) 2005-05-18 2016-08-03 Raptor Pharmaceuticals Inc. Aerosolized fluoroquinolones and uses thereof
PL2656860T3 (pl) * 2005-06-17 2021-11-08 Wisconsin Alumni Research Foundation Preparaty środka zwężającego naczynia i sposoby ochrony komórek podczas chemioterapii i radioterapii przeciwnowotworowej
EP1942108B1 (en) 2005-10-28 2013-09-04 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
EP1961745A1 (en) 2005-12-12 2008-08-27 Ono Pharmaceutical Co., Ltd. Bicyclic heterocyclic compound
WO2007069671A1 (ja) 2005-12-15 2007-06-21 Ono Pharmaceutical Co., Ltd. 二環式複素環化合物
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
EP2120875B1 (en) 2007-02-11 2018-07-11 Map Pharmaceuticals Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
TW200902019A (en) 2007-04-26 2009-01-16 Ono Pharmaceutical Co Dicyclic heterocyclic compound
DE102008007198A1 (de) 2008-02-01 2009-08-13 Infectopharm Arzneimittel Und Consilium Gmbh Oral oder nasal applizierbare Epinephrin- haltige Zubereitungen mit verbesserten Eigenschaften
HUE050147T2 (hu) * 2008-10-07 2020-11-30 Horizon Orphan Llc Tüdõgyulladás csökkentése levofloxacin belélegzése útján
CN102202649A (zh) 2008-10-07 2011-09-28 Mpex医药有限公司 用于改进的药物动力学的氟喹诺酮气雾剂制剂
TWI469965B (zh) 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
ES2511065T3 (es) 2009-06-17 2014-10-22 Ono Pharmaceutical Co., Ltd. Nuevo compuesto imidazopiridina
WO2010151804A1 (en) * 2009-06-26 2010-12-29 Map Pharmaceuticals, Inc. Administration of dihydroergotamine mesylate particles using a metered dose inhaler
PT2473170T (pt) 2009-09-04 2019-08-23 Horizon Orphan Llc Utilização de levofloxacina em aerossol para tratamento de fibrose cística
WO2011066537A1 (en) 2009-11-30 2011-06-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc)
US8598223B2 (en) 2010-06-21 2013-12-03 Ono Pharmaceutical Co., Ltd. Crystalline forms of 4, 4′-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl) butoxy] phenyl} ethynyl)-2-methyl-1H-indole-1,3-diyl] dibutanoic acid, 4,4′-[2-methyl-7-({4-[4-(pentafluorophenyl) butoxy] phenyl} ethynyl)-1H-indole-1, 3-diyl] dibutanoic acid, and 4,4′-[4-fluoro-2-methyl-7-({4-[4-(2, 3, 4, 6-tetrafluorophenyl) butoxy] phenyl} ethynyl)-1H-indole-1, 3-diyl] dibutanoic acid
WO2012074069A1 (ja) 2010-12-02 2012-06-07 小野薬品工業株式会社 新規化合物及びその医薬用途
HUE058753T2 (hu) 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
ES2587856T3 (es) 2011-03-18 2016-10-27 Ono Pharmaceutical Co., Ltd. Derivado de tetrahidrocarbolina
JP6160613B2 (ja) 2012-04-26 2017-07-12 小野薬品工業株式会社 Ｔｒｋ阻害化合物
SG10201700808UA (en) 2013-02-19 2017-02-27 Ono Pharmaceutical Co Trk-INHIBITING COMPOUND
EP3782604A1 (en) 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US9770443B2 (en) 2014-01-10 2017-09-26 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
JP2017504628A (ja) 2014-01-31 2017-02-09 小野薬品工業株式会社 縮合イミダゾール化合物
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
US20210100886A1 (en) 2017-03-30 2021-04-08 Sumitomo Dainippon Pharma Co., Ltd. Wt1 cancer antigen peptides and peptide conjugates comprising the peptides
JPWO2019049891A1 (ja) 2017-09-06 2020-10-15 小野薬品工業株式会社 Ｔｒｋ阻害剤とキナーゼ阻害剤の併用による癌治療方法
EP3804758A4 (en) 2018-05-31 2022-03-02 ONO Pharmaceutical Co., Ltd. BIOMARKER FOR ASSESSING THE EFFECTIVENESS OF AN IMMUNE CHECKPOINT INHIBITOR
US11130773B2 (en) 2018-10-11 2021-09-28 Ono Pharmaceutical Co., Ltd. STING agonistic compound
WO2021025031A1 (ja) 2019-08-05 2021-02-11 小野薬品工業株式会社 免疫チェックポイント阻害薬の有効性判定バイオマーカー
WO2021107125A1 (ja) 2019-11-29 2021-06-03 小野薬品工業株式会社 リゾホスファチジン酸受容体作動活性を有する化合物およびその医薬用途
EP4134134A4 (en) 2020-04-10 2023-12-27 ONO Pharmaceutical Co., Ltd. STING AGONIST COMPOUND
US20230183316A1 (en) 2020-05-12 2023-06-15 Sumitomo Pharma Co., Ltd. Pharmaceutical composition for treating cancer
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
WO2022251679A1 (en) 2021-05-27 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide radicals for use as antiviral treatment for coronavirus infection
WO2023028364A1 (en) 2021-08-27 2023-03-02 Sepelo Therapeutics, Llc Targeted compositions and uses therof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2222976A (en) * 1937-11-15 1940-11-26 Sharp & Dohme Inc Nasal drops
US2728495A (en) * 1951-04-19 1955-12-27 Little Inc A Liquid dispensing device and composition therefor

Also Published As

Publication number Publication date
US2868691A (en) 1959-01-13
GB830426A (en) 1960-03-16

Similar Documents

Publication Publication Date Title
AT10924B (sv)
AT11895B (sv)
AT14123B (sv)
AT11438B (sv)
AT10914B (sv)
AT11477B (sv)
AT11623B (sv)
AT10847B (sv)
AT12140B (sv)
AT12752B (sv)
AT14095B (sv)
AT11475B (sv)
AT11569B (sv)
AT10783B (sv)
AT12016B (sv)
AT1900B (sv)
AT11697B (sv)
AT11483B (sv)
AT11554B (sv)
AT12852B (sv)
AT11375B (sv)
AT2012B (sv)
AT2164B (sv)
AT2206B (sv)
AT2342B (sv)